Bristol Tax Assets vs Investments Analysis
BMY Stock | USD 48.93 0.63 1.30% |
Trend analysis of Bristol Myers Squibb balance sheet accounts such as Short Long Term Debt Total of 43.5 B, Other Current Liabilities of 12.1 B or Total Current Liabilities of 23.4 B provides information on Bristol Myers' total assets, liabilities, and equity, which is the actual value of Bristol Myers Squibb to its prevalent stockholders. By breaking down trends over time using Bristol Myers balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Bristol |
About Bristol Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Bristol Myers Squibb at a specified time, usually calculated after every quarter, six months, or one year. Bristol Myers Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bristol Myers and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bristol currently owns. An asset can also be divided into two categories, current and non-current.
Bristol Myers Balance Sheet Chart
Bristol Myers Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Bristol Myers Squibb uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Bristol Myers' Good Will is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 99.9 B in 2024, whereas Total Stockholder Equity is likely to drop slightly above 15 B in 2024. Add Fundamental
Total Assets
Total assets refers to the total amount of Bristol Myers assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bristol Myers Squibb books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Bristol Myers balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bristol Myers Squibb are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Bristol Myers' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bristol Myers Squibb current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Selling General Administrative is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 12.22 in 2024, whereas Discontinued Operations is likely to drop slightly above 6 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 36.4B | 36.0B | 34.3B | 36.0B | Total Revenue | 46.4B | 46.2B | 45.0B | 47.3B |
Bristol Myers fundamental ratios Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Short Long Term Debt Total | 47.5B | 51.7B | 45.6B | 40.7B | 41.5B | 43.5B | |
Other Current Liab | 7.9B | 10.2B | 10.1B | 13.1B | 11.5B | 12.1B | |
Total Current Liabilities | 18.3B | 19.1B | 21.9B | 21.9B | 22.3B | 23.4B | |
Total Stockholder Equity | 51.6B | 37.8B | 35.9B | 31.1B | 29.4B | 15.0B | |
Property Plant And Equipment Net | 6.3B | 6.7B | 7.0B | 7.5B | 8.0B | 5.2B | |
Net Debt | 35.2B | 37.1B | 31.6B | 31.6B | 30B | 31.5B | |
Retained Earnings | 34.5B | 21.3B | 23.8B | 25.5B | 28.8B | 22.0B | |
Cash | 12.3B | 14.5B | 14.0B | 9.1B | 11.5B | 12.0B | |
Non Current Assets Total | 100.6B | 88.3B | 76.1B | 69.5B | 63.4B | 66.6B | |
Non Currrent Assets Other | 6.6B | 2.1B | 1.7B | 1.0B | 1.9B | 2.0B | |
Cash And Short Term Investments | 12.3B | 14.5B | 14.0B | 9.1B | 12.3B | 12.9B | |
Net Receivables | 7.7B | 8.5B | 12.5B | 13.9B | 15.3B | 16.0B | |
Good Will | 22.5B | 20.5B | 20.5B | 21.1B | 21.2B | 22.2B | |
Common Stock Shares Outstanding | 1.7B | 2.3B | 2.2B | 2.1B | 2.1B | 1.6B | |
Liabilities And Stockholders Equity | 129.9B | 118.5B | 109.3B | 96.8B | 95.2B | 99.9B | |
Non Current Liabilities Total | 59.9B | 61.5B | 51.4B | 43.8B | 43.4B | 45.6B | |
Inventory | 4.3B | 2.1B | 2.1B | 2.3B | 2.7B | 1.9B | |
Other Current Assets | 2.0B | 1.4B | 1.3B | 1.6B | 1.5B | 1.8B | |
Other Stockholder Equity | 18.4B | 18.1B | 13.1B | 6.5B | 1.9B | 2.0B | |
Total Liab | 78.2B | 80.6B | 73.3B | 65.7B | 65.7B | 69.0B | |
Property Plant And Equipment Gross | 6.3B | 5.9B | 11.0B | 11.6B | 12.8B | 13.5B | |
Total Current Assets | 29.4B | 30.2B | 33.3B | 27.3B | 31.8B | 33.4B | |
Accumulated Other Comprehensive Income | (1.5B) | (1.8B) | (1.3B) | (1.3B) | (1.5B) | (1.6B) | |
Short Term Debt | 3.5B | 2.5B | 5.1B | 4.4B | 3.3B | 3.4B | |
Intangible Assets | 64.0B | 53.2B | 42.8B | 36.4B | 27.5B | 28.9B | |
Accounts Payable | 2.4B | 2.7B | 2.9B | 3.0B | 3.3B | 1.9B | |
Short Term Investments | 3.0B | 1.3B | 3.2B | 130M | 816M | 775.2M | |
Other Liab | 15.9B | 12.3B | 11.0B | 7.4B | 8.5B | 4.9B | |
Other Assets | 4.8B | 7.3B | 3.3B | 2.9B | 3.3B | 3.3B | |
Long Term Debt | 43.4B | 48.3B | 39.6B | 35.1B | 36.7B | 38.5B | |
Treasury Stock | (25.4B) | (26.2B) | (31.3B) | (38.6B) | (43.8B) | (41.6B) | |
Property Plant Equipment | 6.3B | 5.9B | 6.0B | 6.3B | 7.2B | 5.8B | |
Current Deferred Revenue | 4.5B | 3.6B | 3.7B | 1.3B | 4.2B | 4.4B | |
Net Tangible Assets | (34.9B) | (36.0B) | (28.2B) | (25.9B) | (23.4B) | (22.2B) | |
Noncontrolling Interest In Consolidated Entity | 96M | 100M | 60M | 57M | 55M | 74.7M |
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.78 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
0.63 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
Moving against Bristol Stock
0.57 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
0.56 | SABSW | SAB Biotherapeutics | PairCorr |
0.54 | DMTK | DermTech Financial Report 2nd of May 2024 | PairCorr |
0.49 | DRUG | Bright Minds Biosciences | PairCorr |
0.48 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.